{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-000864","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.284882+00:00","generated_at":"2026-06-06T06:24:01.838911+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phibro reports Q2 diluted EPS of $0.03 on net income of $1.3M; reaffirms adjusted EBITDA guidance","bullets":["Net sales $249.9M (+2% YoY); Animal Health segment up 6% led by 31% vaccine growth.","GAAP net income $1.3M, diluted EPS $0.03, down from $7.2M and $0.18 a year ago.","Adjusted EBITDA $29.5M (-5% YoY); adjusted diluted EPS $0.33 (-2%).","FY2024 guidance: reaffirmed adjusted EBITDA $106-$112M; GAAP net income lowered to $12-$17M (down 55%).","Includes $4.2M Brazil employment tax litigation charge and $7.5M foreign currency losses from Argentina devaluation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-000864","json":"https://secwatch.observer/filing/0001558370-24-000864.json","markdown":"https://secwatch.observer/filing/0001558370-24-000864.md","text":"https://secwatch.observer/filing/0001558370-24-000864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/0001558370-24-000864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/pahc-20240207x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:24:01.838911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9bd0af051986bc74e533e0bdc243ca544b2be95","claim":"PHIBRO ANIMAL HEALTH CORP reported the fiscal quarter ended December 31, 2023 results: revenue $249.9 million, net income $1.3 million, EPS $0.03. Guidance reaffirmed.","evidence_excerpt":"guidance for the year ending June 30, 2024. ​ Highlights for the three months ended December 31, 2023 (compared to the three months ended December 31, 2022) ​ - Net sales of $249.9 million, an increase of $5.3 million, or 2% - Net income of $1.3 million, a decrease of $5.9 million - Diluted earnings per share of $0.03, a decrease of $0.15 - Adjusted EBITDA of $29.5","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000155837024000864/0001558370-24-000864-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended December 31, 2023"},{"label":"Revenue","value":"$249.9 million"},{"label":"Net income","value":"$1.3 million"},{"label":"EPS","value":"$0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}